Self Study Module 2: Managing RCC Immune-Related Adverse Events (irAEs)
Launch Date:
June 30, 2022
June 30, 2022
Primary Audience:
This activity is intended to meet the educational needs of healthcare professionals involved in the care of patients with renal cell carcinoma.
This module will cover the management of immune-related adverse events in renal cell carcinoma.
Yasser Mohamed Ali Ged, M.B.B.S.
Assistant Professor of Oncology
Johns Hopkins Hospital
Baltimore, MD
Dr. Yasser Ged is a medical oncologist dedicated to the care of patients with genitourinary malignancies. His clinical and research focus is on the management of renal cell carcinoma (RCC). He has completed Medical Oncology Higher Specialist Training with Royal College of Physicians in Ireland and subsequently completed Advanced Medical Oncology Fellowship at the Memorial Sloan Kettering Cancer Center in New York.1.
Outline the elements of a successful multidisciplinary team in the diagnosis and management of immune-related toxicity for patients treated for RCC.
